Collegium Pharmaceutical reported a 9% year-over-year increase in net revenues to $193.5 million for Q1 2026, led by a 36% rise in JORNAY PM sales to $38.9 million and a 14% increase in prescriptions. The company’s pain portfolio also grew 4% to $154.6 million. Collegium plans to close its $650 million acquisition of AZSTARYS in Q2 2026, which is expected to strengthen its ADHD portfolio and boost long-term growth. The company reaffirmed its full-year 2026 guidance and ended the quarter with $421.8 million in cash and equivalents, positioning it well for future growth and shareholder value creation.
The global autoimmune disease therapeutics market is projected to grow from $80.54 billion in 2025 to $137.85 billion by 2035, at a CAGR of 5.52%. Growth is fueled by rising autoimmune disease prevalence, advances in biologics, JAK inhibitors, monocl...
The Vancouver Chinatown Foundation and RBC are hosting Light Up Chinatown! 2026, a free two-day festival on August 8-9 along Columbia Street in Vancouver’s Chinatown. The event features exclusive food collaborations, live music performances, family a...
New research from iSeatz reveals that U.S. travelers are increasingly strategic about travel rewards programs, with 40% treating them as financial optimization tools and 60% belonging to multiple programs. Despite high enrollment, many travelers find...
BlackRock reported quarterly earnings per share of $13.91, surpassing analyst estimates of $12.69, and revenue of $7.08 billion, exceeding expectations of $6.73 billion. The company’s assets under management reached a record $15.3 trillion, a 22% inc...
A regional nonprofit health plan reduced its Transparency in Coverage machine-readable file (MRF) production time from 45 days to less than 24 hours by integrating TALON's platform directly with its claims administration system. This eliminated a com...
